Lilly (LLY) Shows Incremental Growth Opportunities - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Lilly (LLY) Shows Incremental Growth Opportunities - Piper Jaffray
December 10, 2015 6:31 AM EST
Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK) announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA® (pembrolizumab) in a Phase I study across multiple tumor types. Based on the Phase I trial results, the collaboration has the potential to progress to Phase II trials in patients who have been diagnosed with either metastatic breast... More
December 8, 2015 2:14 PM EST
BMO Capital is incrementally positive on Eli Lilly & Co. (NYSE: LLY) following an update on the company's Alzheimers disease (AD) pipeline. BMO rates Lilly at Outperform with a price target of $100.
Analyst Alex Arfaei summarized:
Based on our initial review of the slides,... More
December 8, 2015 7:15 AM EST
Eli Lilly & Co. (NYSE: LLY) declared a quarterly dividend of $0.51 per share, or $2.04 annualized. This is a 2% increase from the prior dividend of $0.50.
The dividend will be payable on March 10, 2016, to stockholders of record on February 12, 2016, with an ex-dividend date of February 10,... More
December 7, 2015 6:34 AM EST
Deutsche Bank upgraded Eli Lilly (NYSE: LLY) from Hold to Buy with a price target of $99.00 (from $85.00). Analyst Gregg Gilbert expects investors interest in Sola to grow, and he pointed out that Jardiance is gaining steam.
"We are raising our peak... More
